Clinical Trial Update: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neladenoson bialanate in chronic heart failure with reduced ejection fraction has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• neladenoson bialanate (neladenoson bialanate)

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2019-04-23